Rationale: The paucity of specific surface markers for cardiomyocytes and their progenitors has impeded the development of embryonic or pluripotent stem cell-based transplantation therapy. Identification of relevant surface markers may also enhance our understanding of the mechanisms underlying differentiation. Objective: Here, we show that cellular prion protein (PrP) serves as an effective surface marker for isolating nascent cardiomyocytes as well as cardiomyogenic progenitors. Methods and Results: Embryonic stem (or embryo-derived) cells were analyzed using flow cytometry to detect surface expression of PrP and intracellular myosin heavy chain (Myhc) proteins. Sorted cells were then analyzed for their differentiation potential. Conclusions: PrP ؉ cells from beating embryoid bodies (EBs) frequently included nascent Myhc ؉ cardiomyocytes. Cultured PrP ؉ cells further differentiated, giving rise to cardiac troponin I ؉ definitive cardiomyocytes with either an atrial or a ventricular identity. These cells were electrophysiologically functional and able to survive in vivo after transplantation. Combining PrP with a second marker, platelet-derived growth factor receptor (PDGFR)␣, enabled us to identify an earlier cardiomyogenic population from prebeating EBs, the PrP ؉ PDGFR␣ ؉ (PRa) cells. The Myhc ؊ PRa cells expressed cardiac transcription factors, such as Nkx2.5, T-box transcription factor 5, and Isl1 (islet LIM homeobox 1), although they were not completely committed. In mouse embryos, PRa cells in cardiac crescent at the 1 to 2 somite stage were Myhc ؉ , whereas they were Myhc ؊ at headfold stages. PRa cells clonally expanded in methlycellulose cultures. Furthermore, single Myhc ؊ PRa cell-derived colonies contained both cardiac and smooth muscle cells. Thus, PrP demarcates a population of bipotential cardiomyogenic progenitor cells that can differentiate into cardiac or smooth muscle cells. (Circ Res. 2010;106:111-119.)
H eart, the first functional organ to develop in vertebrate embryos, contains cardiac, smooth muscle, and endothelial cells. [1] [2] [3] Cardiac transcription factors, such as Nkx2.5 (NK2 transcription factor related, locus 5) and T-box transcription factor (Tbx)5, are first expressed in cardiogenic mesoderm, which is located in the anterior lateral plate mesoderm. 4 Subsequently, genes encoding cardiac-specific structural proteins are expressed in the cardiac crescent. 4 The cardiac crescent then fuses at the ventral midline to form the linear heart tube, which develops into the chambered heart after looping. In the cardiac crescent, endothelial (or endocardial) markers, such as Flk1 (fetal liver kinase-1), do not markedly overlap with cardiomyogenic markers, suggesting that these 2 lineages have already segregated at this stage. Recent studies using embryonic stem (ES) cells have sug-gested the presence of multipotential cardiovascular stem cells that can differentiate into cardiac, smooth muscle, and endothelial cells 5, 6 ; these cells have been identified as Flk1 ϩ and/or islet LIM homeobox 1 (Isl1) ϩ . 7 Intermediate cardiomyogenic progenitor cells may be bipotential, differentiating into both cardiac and smooth muscle cells. 8 Because of the paucity of known specific surface markers, however, these intermediate progenitors have been difficult to characterize. Several studies using ES cells or embryonal carcinoma cells have suggested that temporally regulated Wnt signaling is important for the specification and differentiation of cardiomyocytes. 9 -12 Progeny derived from ES cells, however, are a mixture of different cell types, and additional analysis is needed to define the immediate progenitors of cardiomyocytes more precisely.
In addition to their utility in developmental studies, ES cells or induced pluripotent stem cells are a potential cellular source for cell transplantation therapy to treat damaged hearts. Several groups have shown that transplanted ES cell-derived cells can repair damaged heart tissue. 13, 14 In most of the previous studies, however, the transplanted cells were not purified cardiomyocytes, and including undifferentiated ES cells was often tumorigenic. To improve the efficacy of ES cell-derived cardiomyocytes, cardiomyocytes or committed progenitors should be isolated. Moreover, because functional engraftment requires a large number of cells, scalable and reproducible preparation methods should be developed. To date, few surface markers that can be used to isolate cardiomyocytes have been reported. 15 This has hindered efforts to isolate pure cardiomyocytes.
During course of studies to identify cardiogenesisassociated genes in ES cells, 16, 17 we found that that Prnp, which encodes cellular prion protein (PrP), was expressed in cardiomyocyte-rich embryoid bodies (EBs). In this study, we show that PrP can be used to separate the cardiomyogenic and noncardiomyogenic cellular fractions. Furthermore, we identified a bipotential, PrP ϩ PDGFR␣ ϩ cardiomyogenic population that was able to differentiate into either cardiac or smooth muscle cells depending on Wnt signaling and the culture conditions.
Methods
ht7 cells (derived from the CGR8 cell line; a kind gift from Dr H. Niwa, RIKEN Center for Developmental Biology, Kobe, Japan) and the derivative hcgp7 cell line (Nkx2.5 EGFP [enhanced green fluorescent protein] knock-in) were maintained and differentiated as described previously. 1 Briefly, we created hanging drops (500 cells/drop) of differentiation medium containing 10% fetal calf serum (FCS) and Glasgow Minimum Essential Medium (GMEM). On day 2 of differentiation, medium was added to the plates and the cells were cultured as floating embryoid bodies (EBs). To differentiate EB3 ES cells (derived from the E14tg2a cell line; a kind gift from Dr Niwa), Minimum Essential Medium Eagle Alpha Modification (␣MEM) was used as the basal medium instead of GMEM. Typically, ht7 and hcgp7 cells began to beat spontaneously on day 7, whereas EB3 cells began beating on day 6. The percentages of beating EBs were approximately 100% (ht7 and hcgp7 cells) and 80% (EB3 cells).
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

PrP Is Expressed in ES Cell-Derived Cardiomyocytes
To confirm that Prnp was expressed in EBs during cardiogenesis, we performed RT-PCR analysis. Prnp expression was upregulated by 7-to 8-fold before spontaneous beating began (Online Figure I, A) . In beating EBs, the PrP ϩ area partially overlapped with the area containing sarcomeric tropomyosin protein-expressing cardiomyocytes (Online Figure I, B ). Although the physiological functions of PrP are not yet known, 18 PrP has been detected on the surface membranes of various cell types. 19 To examine the specificity of PrP expression at the cellular level, we used flow cytometry to examine an ES cell line in which EGFP was knocked into the Nkx2.5 locus (Nkx2.5 GFP/ϩ ES cells) 20 ; all of the green fluorescent protein (GFP) ϩ cardiomyocytes expressed PrP on their surfaces on day 7 ( Figure 1A ). Although GFP has been used to isolate cardiomyocytes from beating EBs, we found that GFP expression was not strong enough to allow us to capture all of the Nkx2.5 ϩ cells (see next section). Therefore, we simultaneously detected the surface expression of PrP and intracellular sarcomeric proteins. On day 6 or 7, all of the sarcomeric myosin heavy chain (Myhc) ϩ cells that were derived from the Nkx2.5 ϩ/ϩ ES cell ( Figure 1B) or Nkx2.5 GFP/ϩ ES cell population (not shown) were PrP ϩ , suggesting that the nascent cardiomyocytes were PrP ϩ . Expression of PrP on Myhc ϩ cells gradually started to decrease on day 8. Immunofluorescence in cytospin samples ( Figure  1C ) and cultured cells ( Figure 1D ) further confirmed that PrP can be used to enrich the Myhc ϩ and GATA-binding protein 4 (Gata4) ϩ cell populations.
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PrP Specifically Identifies a Cardiomyogenic Cell Population Derived From ES Cells
To determine whether PrP can be used to enrich not only differentiated cardiomyocytes but also cardiac progenitors, we used reaggregation assays to assess the cardiomyogenic activities of cells sorted from pre-or postbeating EBs. PrP ϩ cells sorted at day 6 (prebeating), day 7 (onset of beating), or day 8 (beating) generated beating reaggregates, whereas PrP Ϫ cells did not ( Figure 2A ). In contrast, the PrP Ϫ fraction gave rise to secondary EBs in Matrigel cultures, suggesting the presence of undifferentiated cells 21 that were not produced from the PrP ϩ fraction ( Figure 2B ). We also found that GFP Ϫ PrP ϩ reaggregates derived from Nkx2.5 GFP/ϩ ES cells had beating foci. Consistent with this result, the GFP Ϫ PrP ϩ cells expressed low levels of mRNA encoding Nkx2.5 and other cardiac transcription factors ( Figure 3A ). Thus, enriching the cardiomyogenic fraction using the cardiogenic marker PrP yielded better results than when enrichment was performed using Nkx2.5 GFP/ϩ knock-in ES cells. Importantly, even without using genetically modified ES cells, we were able to purify the cardiogenic fraction before beating began.
To test whether PrP can be used to separate transplantable cells, we transplanted reaggregates from day 6 EBs under the kidney capsules of nude mice. Immunohistochemical analysis demonstrated that cardiac troponin (cTn)T ϩ cells were pres-ent in the PrP ϩ cell grafts, but not in the PrP Ϫ grafts ( Figure  2C ). Tumor formation was frequently observed in unsorted cell grafts (data not shown) but not in PrP ϩ grafts (41 transplanted aggregates). These results suggested that the PrP ϩ cell population was able to generate cardiomyocytes and survive in vivo for at least 3 weeks.
PrP ؉ Cells Differentiate From Primitive to Definitive Cardiomyocytes
Monolayer cultures of PrP ϩ cells sorted from day 7 or day 8 EBs started to beat within 24 hours. After 5 days of culture, approximately one third of the cells spontaneously beat (data not shown). Single-cell recordings of membrane potentials from 16 of 18 quiescent cells revealed action-potential profiles similar to those of working (atrial or ventricular) cardiomyocytes ( Figure 3A ). The rest of the cells displayed sinus nodal cell-like spontaneous beating activity. Pharmacological studies using multielectrode arrays indicated that the cultured PrP ϩ cells were responsive to isoproterenol and carbamylcholine, suggesting the presence of functional ␤ adrenergic receptors and sinoatrial cardiomyocytes, respectively ( Figure 3B ). Immunofluorescence indicated that PrP ϩ cells differentiated into cTnI ϩ (a definitive marker of cardiomyocytes) cells. These were either myosin light chain 2v (Mylc2v) ϩ or Mylc2v Ϫ ( Figure 3C ). A few atrial natriuretic peptide (ANP) ϩ cells were also detected.
To examine the cell types quantitatively, we performed flow cytometry with atria and ventricles from mouse embryos as reference samples (Online Figure I, E ). Among the atrial and ventricular cells from embryonic day (E)13.5 embryonic heart, 25% and 2% to 4% were ANP ϩ , respectively. Myosin light chain 2a (Mylc2a) was detected in both the atrial and ventricular cells, although higher levels were observed in atrial cells. Thus, neither ANP nor Mylc2a can be used to distinguish atrial cells from ventricular cells. In contrast, all embryonic ventricular cells were Mylc2v ϩ , whereas all atrial cells were Mylc2v Ϫ . Approximately 50% of cultured PrP ϩ cells were Mylc2v ϩ , although the expression level varied between cells ( Figure 3D ). Consistent with the immunofluo- rescence results, only 1% to 2% of the cells were ANP ϩ . The PrP ϩ cell fraction initially contained cells expressing Myhc and cTnT but not cTnI (data not shown). 20, 22 Interestingly, after 10 to 13 days of culture, 90% of the cells differentiated into cTnI ϩ cardiomyocytes. Collectively, these results suggested that PrP ϩ cells differentiated from cTnI Ϫ to cTnI ϩ cardiomyocytes with an atrial or a ventricular identity.
The PrP ؉ PDGFR␣ ؉ Population Contains Myhc ؊ Cardiomyogenic Progenitors
Although PrP expression was first detected at day 5, we were unable to enrich the cardiomyogenic population using this marker until day 6. To determine whether combination with other surface markers would allow better enrichment of the progenitor population at day 5, we examined Flk1, c-kit, and platelet-derived growth factor receptor (PDGFR)␣ as secondary surface markers. Flk1 is a marker of cardiovascular progenitors: common progenitors for cardiac, smooth muscle, and endocardial cells. 5 PrP ϩ cells expressed a very low level of Flk1 on day 5 and even less on day 6 (Online Figure IV, A) , suggesting that PrP ϩ cells may have already diverged from the vascular lineage. c-kit, which is reported to be a cardiovascular stem cell marker in adult and embryonic heart, 8 was not expressed on PrP ϩ cells. PDGFR␣ is widely expressed in mesoderm, including the cardiac lineage, although its expression is gradually downregulated in heart tube (elsewhere 23 and Online Figure VI ). PrP expression was first observed on day 5 on PDGFR␣ ϩ and PDGFR␣ Ϫ cells ( Figure 4A ). Molecular analysis indicated that the PrP ϩ PDGFR␣ ϩ cell fraction from day 5 EBs expressed cardiac marker genes, including Nkx2.5, Tbx5, and Isl1, whereas the PrP ϩ PDGFR␣ Ϫ cell fraction did not ( Figure 4B and 4C) . Consistent with these data, only the PrP ϩ PDGFR␣ ϩ cell fraction gave rise to beating reaggregates (Online Figure  IV, D) . These results suggested that double-positive PrP ϩ PDGFR␣ ϩ cells, hereafter referred to as PRa cells, are the earliest known cardiomyogenic population.
PRa Cells Differentiate Into Cardiac Cells and Smooth Muscle Cells
To test the cardiomyogenic potential of PRa cells, we used PRa cells sorted from day 5.5 EBs, at which point Myhc was not expressed (data not shown), and directly differentiated the cells as 3D reaggregates (3D cultures) or as sparsely cultured 2D monolayers (2D cultures). The reaggregates developed into beating cardiomyocytes, whereas the monolayer cultures did not (Online Figure V,  D) . Reaggregate cultures expressed such cardiac-specific genes as Myl7 (encoding Mylc2a), Myh6 (encoding myosin heavy chain ␣), and Tnni3 (encoding cTnI) ( Figure 5A ). In contrast, smooth muscle genes, including Tagln (encoding SM22␣), Acta2 (encoding smooth muscle actin, SMA), and Myh11 (encoding smooth muscle myosin heavy chain [SMMyhc]), were expressed in the monolayer cultures. Interestingly, adding Wnt3a (wingless-related MMTV integration site 3A) to the reaggregates inhibited cardiac differentiation ( Figure 3C ). Wnt, however, did not increase the levels of smooth muscle markers, suggesting that it did not drive the progenitors to a smooth muscle fate. Immunostaining experiments revealed that aggregates expressed the cardiac muscle proteins Myhc and cTnI, whereas the . PrP ϩ cells differentiate into cTnI ϩ definitive cardiomyocytes with an atrial or a ventricular identity. A, Traces of the membrane potential recorded from a single PrP ϩ cell. PrP ϩ cells sorted on day 8 were cultured for 5 days. Approximately, one third of the cells spontaneously beat (data not shown). Sixteen of 18 quiescent cells exhibited a working myocardiumtype (atrial or ventricle) action potential, whereas the rest exhibited a pacemakertype action potential. Action potentials were elicited at 1 Hz. B, Pharmacological analysis of PrP ϩ cells. PrP ϩ cell aggregates were analyzed using multielectrode arrays and isoproterenol (ISO) (1 mol/L) or carbamylcholine (CCh) (10 mol/L). All aggregates were sensitive to CCh, suggesting that they contained atrial cells. Error bars represent the SE (nϭ9 independent samples for each group). *PϽ0.05 from a paired t test. C, Immunofluorescence analysis for cTnI (a definitive cardiomyocyte marker), Mylc2v (a ventricle marker), and ANP (a chamber myocardium marker). PrP ϩ cells sorted on day 7 were cultured on gelatin-coated dishes for 1 week. The number of cTnI ϩ cells increased during the culture. Mylc2v ϩ cells were frequently observed, whereas the percentage of ANP ϩ cells was low (1% to 2%). Arrows indicate cells that are ANP ϩ MLC2v ϩ , a profile characteristic of left ventricular cardiomyocytes. D, Flow cytometric analysis of PrP ϩ cell cultures. Sorting on day 7 revealed that the cardiomyocytes were cTnT ϩ but not cTnI ϩ (data note shown). After culturing the cells for 13 days, 90% to 95% expressed both cTnT and cTnI, 50% to 60% expressed Mylc2v, and 1% expressed ANP. Control experiments using embryonic heart and PrP Ϫ fractions are shown in Online Figure III. monolayer cells expressed such smooth muscle proteins as SMA, SM22␣, and calponin ( Figure 5B ). SMMyhc, a very specific marker of smooth muscle cells, 8 was also detected in the monolayer cells. These results suggested that the PRa cell fraction contained 2 different lineages and/or bipotential progenitors. To examine the latter possibility, we next cultured single cells isolated from days 5 to 5.5 EBs in methylcellulose (MEC). Typically, Ϸ100 colonies Fig V) , were allowed to differentiate as reaggregates (3D) or sparse monolayers (2D) with or without Wnt or the Wnt inhibitor Dkk1 (dickkopf homolog 1). After 2 days of culture, cardiac (Myl7, Myh6, Tnni3) and smooth muscle (Tagln, Acta2, Myh11) markers were analyzed in RT-PCRs. Error bars represent the SEMs (nϭ3 independent samples for each group). B, Immunostaining of 3D or 2D cultures of PRa cells for cardiac and smooth muscle marker proteins. PRa cells sorted on day 5.5 were aggregated in an ultralow binding plate for 2 days and then transferred to a gelatin plate for 3 days (3D32D) or were cultured on only a gelatin plate for 5 days (2D). Beating aggregates (marked with the dotted lines) strongly expressed the cardiac proteins Myhc and cTnI. Monolayer cells expressed a number of smooth muscle cell markers, including SMA, SM22, calponin, and SMMyhc. C, Expansion and differentiation of single PRa cells. PRa cells sorted on day 5.5 were expanded in MEC at clonal density for 6 days and colonies derived from single cells were transferred to gelatin-coated multiwell plates for immunostaining. Colonies composed of SMA ϩ Myhc Ϫ smooth muscle cells only (S only), SMA ϩ Myhc Ϫ smooth muscle cells and SMA ϩ Myhc ϩ cardiac muscle cells (SϩC), Myhc ϩ SMA ϩ cardiac muscle cells only (C only), or platelet/endothelial cell adhesion molecule-positive endothelial cells (E) were counted. Error bars represent the SEMs (nϭ5 independent samples for each group).
were created from 5000 single-cell isolates (Online Figure  III, C) . Colony formation was inhibited by the addition of the Wnt inhibitor Dkk1 (dickkopf homolog 1) and promoted by Wnt3a or a glycogen synthase kinase-3␤ inhibitor, suggesting that the proliferation of PRa cells was dependent on canonical Wnt signaling. Individual colony analysis indicated that approximately 25% of Myhc Ϫ PRa cell-derived colonies expressed both smooth and cardiac muscle proteins ( Figure 5C ), whereas the rest of the colonies expressed only smooth muscle proteins. Endothelial cell differentiation, assessed based on platelet/endothelial cell adhesion molecule expression, was not observed. These results strongly suggested that the Myhc Ϫ PRa cells contained bipotential (cardiac and smooth muscle) progenitor cells.
Expression of PrP in Mouse Embryos
We next examined the spatial and temporal profiles of PRa cells in embryos. Transgenic mouse studies using ␤-galactosidase suggested that Prnp is expressed in embryonic heart at E8.5. 24 Endogenous expression of PrP mRNA and protein during embryonic early stages (E7 to E7.5) has not been adequately elucidated, however. 25, 26 To examine the expression of PrP in early mouse embryos, we performed whole-mount in situ hybridizations and immunohistochemical analysis. During early developmental stages, we observed specific expression of Prnp mRNA in the cardiac mesoderm during late-bud stage ( Figure 6A ). We also detected PrP protein in the cardiac crescent at headfold stages and in the heart tube at somite stages (Online Figure VI) . On the other hand, PDGFR␣ expression was observed widely in the mesoderm, including cardiac mesoderm, of late-bud to 1 to 2 somite stage embryos (Online Figure VI) . PDGFR␣ expression gradually decreased in cardiomyocytes after they reorganized into the heart tube.
We next analyzed PrP expression in mouse embryos using flow cytometry. As expected from the immunohistochemical analysis, PrP ϩ cells were either PRa cells or PrP ϩ PDGFR␣ Ϫ cells from the E7 pool (primarily consisting of presomite stage mouse embryos) and the E8 pool (primarily consisting of somite stage mouse embryos) (Online Figure VII, A) . As observed in ES cell-derived cells, little overlap between PrP and Flk1 expression was detected at these stages. Sorting using PrP clearly enriched the cardiac marker-expressing cells from the E8 pool (Online Figure VII, B ), suggesting that PrP was a specific marker of cardiomyocytes at these stages. To determine whether the PRa population contained both Myhc ϩ cardiomyocytes and Myhc Ϫ progenitor cells, flow cytometric analysis was performed with embryos at different developmental stages. Myhc ϩ cells were detected at 1 to 2 somite stages but not at presomite stages. The nascent Myhc ϩ cells were exclusively identified in the PRa cell Figure 6 . PrP is expressed before Myhc in mouse embryonic cardiac mesoderm. A, Whole-mount in situ hybridization analysis for Prnp mRNA (a through c) and immunohistochemical analysis for PrP protein (d). Note that Prnp mRNA was expressed in the cardiac mesoderm (CM) beginning at the late-bud stage (LB) and expression was maintained in the cardiac crescent (Cc) and heart tube (Ht) at the late headfold stage (LHF), 1 to 2 somite stage (1 to 2ss), and 3 to 4 somite stage (not shown). PrP was also expressed in the node (N). PrP protein was detected in the cardiac crescent at the late headfold stage (see Online Fig. VI) . At the 5to 6-somite stage, expression was also observed in the sinus venosus (Sv). Nonspecific staining was detected in extraembryonic membrane (EM). B, Flow cytometric analysis of surface and intracellular proteins. After staining the cell surfaces with anti-PrP and anti-PDGFR␣ antibodies, cells were fixed and permeabilized. Myhc ϩ cells were first detected in 1-to 2-somite stage embryos and were exclusively observed in the PRa fraction. C, RT-PCR analysis of sorted cells from pools of late-bud to late headfold embryos (LB-EHF-LHF) or 1 to 2 somite embryos (1 to 2 ss). Note that the PRa cell fraction from presomite stages, before Myhc was expressed, was specifically enriched with cardiac markers. Error bars represent the SEMs (nϭ3 independent samples for each group). fraction ( Figure 6B ). PRa cells sorted from presomite stage embryos (a pool of late-bud to headfold stage embryos) expressed mRNA encoding Nkx2.5, Isl1, Tbx5, and other cardiac transcription factors ( Figure 6C ). PrP ϩ PDGFR␣ Ϫ cells, probably from such extracardiac regions as node, did not express cardiac genes. These results suggested that the embryonic PRa population, similar to ES cell-derived PRa cells, contained Myhc ϩ nascent cardiomyocytes as well as Myhc Ϫ cardiomyogenic progenitors.
Commitment Status of PRa Cells Derived From Mouse Embryos
We then cultured PRa cells from mouse embryos. Similar to cells from EBs, PRa cells from embryos formed colonies in MEC cultures ( Figure 7A ). Immunostaining analysis revealed that one of ten colonies derived from an E7 pool contained Myhc ϩ cells ( Figure 7B-C) . The other colonies expressed the smooth muscle proteins SMA, SM22, and SMMyhc. PRa cells from the E7.5 pool frequently generated Mhyc ϩ cardiomyocyte-containing colonies (10 of 12). These samples also contained smooth muscle colo-nies, suggesting from the presence of bipotential progenitors. PRa cells from the E8 pool generated small beating cardiac colonies. Such beating colonies exclusively contained cardiomyocytes, and not smooth muscle cells, suggesting that the isolated cells were committed to the cardiomyogenic lineage. These results suggested that PRa cells isolated from the cardiac mesoderm could differentiate into either cardiac or smooth muscle cells. Thus, PRa cells from mouse embryos and EBs may share common differentiation and proliferation potentials.
Discussion
In this study, we have demonstrated that the surface marker PrP can be used to enrich cardiomyocytes derived from ES cells. Several groups have examined methods to enrich cardiomyocytes using gravity or introduction of a selectable marker. Surface markers that allow cardiomyocytes to be selected directly, however, have not been extensively elucidated. Importantly, up to 90% of cells derived from PrP ϩ cell cultures expressed cTnI (a marker for definitive cardiomyocytes). The other cells expressed SMA, suggesting that the cultures contained at least 2 different lineages. To improve the purity of the population, other markers or directional differentiation methods should be combined with PrP expression. We also showed that the cultured PrP ϩ cells differentiated into both atrial and ventricle cardiomyocytes. Hcn4 protein, a specific marker for sinus node, was barely detectable. Because spontaneous pacemaker-like activity was detected in immature atrial or ventricular cardiomyocytes, PrP ϩ cells may not have differentiated into mature sinus node cells, at least under our culture conditions. Cells expressing ANP, a marker of chamber myocardium, 27 were not found in significant numbers in the PrP ϩ cell cultures, suggesting that the PrP ϩ cells had not differentiated into chamber myocardium cells. Consistent with this idea, flow cytometric analysis of the expression patterns of Mylc2v and ANP produced results that were more similar to those observed for E9.5 heart than for E13.5 heart.
At earlier stages, PrP did not define a cardiomyogenic population. The PrP ϩ PFGFR␣ ϩ fraction (PRa cells) contained nascent cardiomyocytes and their progenitors. It would be interesting to understand the relationship between PRa cells and previously described cardiovascular progenitor/stem cells. Because PRa cells did not markedly express Flk1, they may have segregated from the endothelial lineage. Consistent with this idea, we did not observe endothelial cell differentiation from PRa cell-derived cells even in the OP9 culture system, which efficiently supported endothelial cell differentiation (Online Figure V) . The proliferation and differentiation of PRa cells are regulated positively and negatively by Wnt signals, respectively. The presence of Isl1 ϩ cells in the PRa cell population (Online Figure IV, E) indicates that PRa cells represent an intermediate progenitor, located between Isl1 ϩ multipotential cells and committed cardiomyocytes. Other groups have described bipotential progenitors, such as c-kit ϩ Nkx2.5 ϩ cells and Tbx18 ϩ epicardial cells. 28, 29 Because PRa cells did not display surface expression of c-kit, they are likely not related to c-kit ϩ Nkx2.5 ϩ cells. Interestingly, we observed Tbx18 expression in PRa cellderived 2D cultures but not in 3D cultures (data not shown). Recent studies showed that the Nkx2.5 ϩ lineage also diverges into Tbx18 ϩ epicardial cells. 30 Thus, it would be intriguing to know if PRa cells can differentiate into epicardial cells.
Embryonic localization in the cardiac crescent and their limited differentiation potential strongly suggest that PRa cells include progenitors from the primary heart field. Consistent with this idea, PRa cells sorted from presomite-stage embryos expressed Tbx5. On the other hand, PRa cells also include progenitors from the secondary heart field, because they also expressed Tbx1 and Isl1. Flow cytometric analysis further revealed that PRa cells were present in the outflow tract segment, which is derived from the secondary lineage (Online Figure VII, C) . As in the early somite stages, outflow-derived PRa cells included Myhc ϩ cells. Thus, PRa can serve as a pan-marker for cardiomyogenic progenitors independent of the heart field lineage. Interestingly, compared with embryo-derived PRa cells, EB-derived PRa cells expressed lower levels of Tbx1. This suggests that, under our culture conditions, primary heart lineage progenitors preferentially developed. However, it should be determined whether or not EB-derived PRa cells differentiated into outflow cardiomyocytes.
Based on molecular studies and in vitro cultures of isolated cells, we propose that PRa cells include a cardiomyogenic population, which can differentiate into cardiac or smooth muscle cells (Online Figure VIII) . Considering their limited differentiation potential, PRa cells may be downstream of Flk1 ϩ cells, separate from the endothelial lineage. Immediate early progenitors may be in the Flk1 ϩ PDGFR␣ ϩ fraction, because this transient cell faction (observed on day 5) specifically expressed Mesp1 (data not shown). Multipotent or pluripotent stem cells, including induced pluripotent stem cells, are expected to be a powerful tool for transplantation therapy and drug screening. Testing the ability of ES cellderived cardiomyocytes to rescue in vivo heart function has been hampered by a lack of markers that allow scalable purification of the population without recourse to the genetic manipulations required to insert lineage-or stage-specific selectable markers. The mouse cell surface marker PrP defines a cardiogenic population in differentiating ES cells, enabling efficient isolation and enrichment of ES cellderived cardiomyocytes.
